Phase 3 Clinical Trials With Primary Completion Dates in October 2020

This is a list of Phase 3 trials with primary completion dates in October 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
BBIBrickell Biotech, Inc.2020-10-01Phase 3NCT03948646Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
BBIBrickell Biotech, Inc.2020-10-01Phase 3NCT03836287Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
BCLIBrainstorm Cell Therapeutics Inc.2020-10-01Phase 3NCT03280056Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients
GNFTGenfit SA2020-10-01Phase 3NCT02704403Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
GRTXGalera Therapeutics, Inc.2020-10-01Phase 3NCT03689712ROMAN: A Study to Investigate the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
RETAReata Pharmaceuticals, Inc.2020-10-01Phase 3NCT03068130Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
TNXPTonix Pharmaceuticals Holding Corp.2020-10-01Phase 3NCT04172831A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia